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Abstract
Objectives: The objective of this review was to charac-
terize the use of biomarkers of male hypogonadism in
childhood and adolescence.
Contents: The hypothalamic-pituitary-gonadal (HPG) axis
is active during fetal life and over the first months of
postnatal life. The pituitary gland secretes follicle stimu-
lating hormone (FSH) and luteinizing hormone (LH),
whereas the testes induce Leydig cells to produce testos-
terone and insulin-like factor 3 (INSL), and drive Sertoli
cells to secrete anti-Müllerian hormone (AMH) and inhibin
B. During childhood, serum levels of gonadotropins,
testosterone and insulin-like 3 (INSL3) decline to unde-
tectable levels, whereas levels of AMH and inhibin B
remain high. During puberty, the production of gonado-
tropins, testosterone, and INSL3 is reactivated, inhibin B
increases, and AMH decreases as a sign of Sertoli cell
maturation.
Summary and outlook: Based on our knowledge of the
developmental physiology of theHPGaxis, these biomarkers
can be used in clinical practice to interpret the physiopa-
thology of hypogonadism. Additionally, these markers can
have diagnostic value in different forms of hypogonadism
that may appear during childhood and adolescence.
Keywords: ambiguous genitalia; cryptorchidism; gonadal
dysgenesis; hypergonadotropic hypogonadism; hypo-
gonadotropic hypogonadism; micropenis; sexual devel-
opment disorders; testicle.
Introduction
Hypogonadism in males is typically defined as a testicular
failure characterized by androgen deficiency. Although this
definition is widely accepted in the endocrinology of adults,
it is hardly useful in pediatric patients [1]. To better under-
stand the difficulties that may arise from an inadequate use
of this definition of hypogonadism in children and adoles-
cents, it is necessary to consider the developmental physio-
pathologyof thehypothalamic-pituitary-gonadal (HPG) axis.
Developmental physiology of the
HPG axis
Testis differentiation occurs by the 6th week of embryonic
development (week 8 after last menstrual period (LMP))
before HPG axis function is activated [2]. The seminiferous
cords originate from interaction of Sertoli cells, which sur-
round germ cells, whereas Leydig cells appear in interstitial
tissue. Sertoli cells secrete Anti-Müllerian hormones (AMH),
which cause the regression of paramesonephric ducts or
Müllerian ducts (primitive uterus andFallopian tubes) during
the 8th and 9th week of intrauterine life (Figure 1). At this
stage, AMH is independent from pituitary gonadotropins,
albeit from the secondhalf of gestation it is sensitive to follicle
stimulating hormone (FSH) [3]. Sertoli cells also secrete
inhibin B, which is stimulated by FSH and controls negative
feedback effect on pituitary production of FSH [4, 5]. Leydig
cells produce androgens (Figure 1),which causemesonephric
ducts (Wolffian ducts) to develop into epididymis, vas def-
erens, and seminal vesicles. In addition, androgens induce
the differentiation of the urogenital sinus and formation of
external genitalia [6]. The synthesis of androgens is activated
by human chorionic gonadotropin (hCG) action during the
first trimester of gestation, and of pituitary luteinizing hor-
mone (LH) in a later stage. Leydig cells also secrete insulin-
like 3 factor (INSL3) which is in conjunction with androgens
and induce the descent of the testis into the scrotal sac [7, 8].
Concentrations of all gonadal axis hormones in blood
are low at birth and increase progressively from the first
week of life [9]. Levels of gonadotropins, testosterone, and
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INSL3 are similar to those of adults until the sixth month of
life, when they start to decline to low or undetectable levels
[10]. High AMH levels persist in childhood, which is indic-
ative of Sertoli cell immaturity [11, 12], whereas inhibin B
partially decreases but remains detectable [5]. During
childhood, the testicles grow in an unnoticeable wayloffset
4.5mm in clinical terms, being Sertoli cell population the
one that most contributes to testes volume [13]. Despite the
exposure to high androgen concentrations until 6 months of
life, Sertoli cell maturation does not start, as they do not
express androgen receptor [14–16]. After the first year of life,
androgen receptor expression appears. However, Sertoli
cells remain immature in childhood owing to low testos-
terone levels [17]. Germ cells only proliferate by mitosis but
do not enter meiosis, which prevents spermatogenesis.
Pubertal onset is characterized by a reactivation of the
gonadotrope, which starts the cyclical production of FSH
and LH. FSH induces the proliferation of immature Sertoli
cells. Thus, testis volume starts to increase progressively.
LH induces Leydig cell secretion of testosterone. Increased
levels of intratesticular testosterone induce the maturation
of Sertoli cells, which refrain AMH production and stimu-
late inhibin B secretion [13]. Another characteristic of
mature Sertoli cells is their ability to develop the blood-
testis barrier (BTB) and functionally sustain adult sper-
matogenesis [18]. The significant proliferation of germ cells
causes a remarkable increase of testes volume.
Biomarkers of the HPG axis
Pituitary hormones: LH and FSH
Gonadotropins LH and FSH share the alpha subunit with
pituitary thyrotropin (TSH) andhCG, andowe their specificity
to their beta subunit. LHandFSHare secretedby thepituitary
Figure 1: Ontogeny of the hypothalamic-pituitary-gonadal axis (HPG) in males and impact on the clinical presentation of hypogonadism.
Gonad differentiation occurs during the first trimester of fetal life separately from pituitary gonadotropins. Testicular androgens and the anti-
Müllerian (AMH) hormone inducemale genital differentiation, and its absence results in female development. Hypogonadism in this period of
life induces the development of ambiguous genitalia or female genitalia in XY individuals. In the second and third trimester, androgens induce
testicular descent and penile growth. Primary and secondary hypogonadism result in micropenis, microorchidism, and/or cryptorchidism in
newborns with male genitalia. During the first days of postnatal life, gonadotropin and androgen secretion is activated. Hypogonadism
prevents penile growth. During childhood, gonadotropins and testosterone are generally low or even undetectable. Hypogonadism
established in this period is not associatedwith evident clinical signs and can only be detected by AMHor inhibin B determination. At puberty,
the HPG axis reactivates, thereby driving the typical development of secondary sexual characteristics. Hypogonadism can inhibit puberty
totally or partially or cause infertility and sexual dysfunction in later stages of life. This Figure was modified using BioRender ({ut1}https://
biorender.com/) under the authorization of [1]. © 2019 Elsevier Ltd.
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gonadotrope in response to the stimulus of gonadotropin-
releasing hormone (GnRH) produced by the hypothalamus.
Luteinizing hormone
LHbinds to luteinizing hormone choriogonadotropin receptor
(LHCGR), which is stimulated by LH and hCG and is present
in Leydig cell membranes. LH stimulates testicular ste-
roidogenesis resulting in an increase in circulating testos-
terone concentrations. LH has a trophic effect on Leydig
cells, thereby inducing their proliferation (hyperplasia) and
stimulating INSL3 secretion [19, 20]. Decreased levels of LH
induce Leydig cell dedifferentiation into mesenchymal pre-
cursors and a reduction of androgen and INSL3 levels after
the 3 to 6 month period of postnatal activation, which is
typically known as "mini-puberty" [10, 13, 21]. During pu-
berty, which generally begins at any point from the ages of 9
to 14 [22], LH stimulates the proliferation of Leydig cells and
the production of androgens and INSL3.
Circulating LH levels are very low during the first
postnatal hours [23] and increase during the first week of
life [9] to remain at similar levels to those of puberty until 3
to 6 months of life [10]. Then, serum LH declines to non-
detectable levels by a series of well-known mechanisms
and remains stable until pubertal onset (Figure 2). During
puberty, LH is secreted in a pulsatile fashion at 90 min
intervals first during the night and later the whole day [24].
Circulating LH levels increase progressively during puberty
following Tanner stages [12]. As it occurs with other
gonadal axis hormones, LH levels must be determined
based on Tanner stage [25] rather than age. This is due to
considerable inter-individual variability in the age of pu-
bertal onset and end in the general population [22].
Follicle stimulating hormone
FSH binds to its specific receptor follicle stimulating hor-
mone receptor (FSHR), which is expressed in Sertoli cell
membranes. FSH stimulates immature Sertoli cell prolifer-
ation (from fetal life until the onset of puberty) and de-
termines testes size in this stage of life. FSH stimulates the
secretion ofAMH [26] and inhibinB [27]. As LH, serumFSH is
Figure 2: Ontogeny of the evolution of
testicular volume from birth to adulthood.
Seminiferous cords (Sertoli cells + germ
cells) are themain component of the testes.
From birth and during the prepubertal
period (i. e., until 9–14, Tanner stage 1), the
volumeof seminiferous cords is determined
by Sertoli cells, whereas germ cell
proliferation determines testicular volume
during puberty (i. e., Tanner stages 2 to 5)
(adult spermatogenesis). This Figure was
modified using BioRender (https://
biorender.com/) under the authorization of
[1]. © 2019 Elsevier Ltd.
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low at birth [23] and progressively increases during the first
week of life [9]. In males, FSH concentrations are slightly
lower than those of LH in "mini-puberty" [12]. During
childhood, FSH also declines, but not as steeply as LH
(Figure 2). As a result, circulating FSH levels in this stage of
life exceed those of LH [12, 28].
Testicular hormones
Testicles contain two cell populations with endocrine
function: Sertoli cells and Leydig cells. Endocrine activity
of Leydig cells is clinically informative during postnatal
activation or "mini-puberty" and puberty, whereas Sertoli
cell activity is more informative in childhood.
Testosterone
Circulating levels of testosterone and LH undergo the same
variations (Figure 2) i. e., they are low at birth [23] and
progressively increase during the first month of life [9].
Although it is recommended that determination of steroid
levels be performed by immunoassay [29], other steroids
may be unspecifically detected during the first two and
three weeks of life; therefore, extraction is required prior to
determination to avoid overestimation [9]. From 3 to
6 months of life, circulating testosterone in plasma de-
creases to undetectable levels, and increases in Tanner
stage 2 or 3 [12]. During childhood, estimation of the
functional activity of Leydig cells can be based on circu-
lating testosterone levels after hCG stimulation (2 to 3 IM
injections of 1,500 to 2,500 IU at 48 h intervals [30].
Insulin-like 3 or Insulin-like 3 factorTesticular secre-
tion of INSL3 is similar to that of testosterone [10, 13, 21].
However, INSL3 only reflects the long-term trophic effect of
gonadotropins on Leydig cells, and INSL3 determination is
not informative after acute hCG stimulation [19].
Anti-Müllerian hormoneAMH is a distinctive marker of
prepuberal Sertoli cell population (Figure 2). Serum AMH
decreases at birth and increases during the first weeks of
life [9] to peak at 2–3 years of age, being 100-fold higher in
males [11, 12, 31]. This is of clinical relevance, as samples
from males require dilution for AMH concentrations to be
within the range of detection of the immunoassays
currently used in clinical laboratories.
Although basal AMH production is not dependent on
gonadotropins [32], FSH stimulates testicular AMH secre-
tion [26, 33–35]. In turn, increased testosterone concen-
trations inhibit AMH secretion [18, 36]. However, the
increase of circulating androgen levels induced by medi-
cation is not enough to inhibit AMH [37]. Similarly, inmales
younger than 1 year, testosterone does not inhibit AMH
production, as Sertoli cells do not express the androgen
receptor in this stage of life [14, 38].
Inhibin B
Inhibins are dimeric proteins secreted by the gonads [39]
with two isoforms with the same alpha subunit but distinct
beta subunits. Inhibin B, which is complexed with a beta-B
subunit, is the only form of inhibin with physiological
relevance in males [40, 41]. In men, inhibin B is secreted in
high amounts by Sertoli cells [4] and its production is
stimulated by FSH [27, 34]. At the same time, inhibin B is
the main inhibitor of FSH secretion from the pituitary
gland. Levels of FSH are very elevated in patients with a
depressed secretion or loss of inhibin B as in anorchia.
However, during childhood, FSH may not be elevated [28],
which is indicative of the hypothalamic–pituitary latency
(gonadotrope) during that period of life.
Levels of inhibin B increase during the first weeks of
life [9] reaching adult concentrations at 2 years of life [42,
43]. From 3 years of age, levels of inhibin B decrease
slightly, but remain detectable (Figure 2) and higher than
in girls. At puberty, inhibin B levels rise to a peak at Tanner
stage 2 or 3 [4, 43, 44]. Thereafter, levels of inhibin B reflect
Sertoli cell activity and interaction with germ cells.
Male hypogonadism
Male hypogonadism in adults has been defined as [1] a
testicular dysfunction reflected in androgen deficiency
with or without impaired sperm production [45]. Based on
the developmental physiology described above, all male
infants and children would meet the criteria for hypo-
gonadism, as they do not produce testosterone or sperm.
However, Sertoli cells are active during childhood, thereby
inducing a slight testicular growth (Figure 2) and the pro-
duction of AMH [46] and inhibin B [42, 43]. Determination
of Sertoli cells is useful as an indicator of testicular func-
tion in the pediatric population. For a definition of male
hypogonadism to be applicable to children, diagnosis of a
diminished testicular function should be established tak-
ing the testicular function expected for the age of the pa-
tient as a reference, which may involve Sertoli cells (AMH,
inhibin B), Leydig cells (testosterone, INSL3), and/or germ-
cells [47].
Considering this principle, male hypogonadism should
not only be classified based on the constituent of the HPG
axis primarily affected, but also on the period of life and the
testicular population primarily affected (Tables 1 and 2).












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Hypogonadism may be caused by a primary defect in the
hypothalamus or pituitary gland or an abnormality in the
gonads. In rare cases, both, the hypothalamic–pituitary
axis and the testes present a primary defect, which origi-
nates dual or combined hypogonadism [47].
Primary hypogonadism
In adult medicine, primary hypogonadism (testicular or
peripheral) is known as "hypergonadotropic" [1, 45] and is
characterized by a primary defect in the testis. Deficient
inhibin B and testosterone production reduces the negative
feedback effect on the HPG axis, which results in an
increased production of gonadotropins. This phenomenon
does not always occur resulting in LH and FSH dissocia-
tion. Some examples of primary hypogonadism include
Klinefelter syndrome, Testicular regression syndrome
(TRS), and orchitis, to name a few.
Secondary hypogonadism
Secondary hypogonadism (hypothalamus–pituitary or
central) is known as "hypogonadotropic" in adultmedicine
[1, 45] and is characterized by a primary defect in the hy-
pothalamus or the pituitary gland. Impaired production of
LH and FSH prevents the normal development of Leydig
cells and seminiferous cords (Sertoli cells and germ cells).
The developmental physiology of the HPG axis makes the
diagnosis of these conditions challenging. LH and FSH
dissociation may also occur. Examples of secondary
hypogonadism include Kallmann syndrome, multi-
hormonal pituitary hormone deficiency, and pituitary
hormone deficiency after central nervous system surgery,
to name a few.
Dual hypogonadism
There are rare conditions where both, the HPG axis and the
gonads present primary damage. In contrast with primary
and secondary hypogonadism, impairment of all testicular
cell populations is concomitant and not secondary. Dual
hypogonadism conditions include Prader–Willi syndrome
and gonadal failure in oncologic patients treated with
chemotherapy and cranial radiotherapy, among others.
Generalized or dissociated gonadal failure
Generalized hypogonadism
In these cases, all testicular cell populations exhibit pri-
mary damage, concentrations are decreased, and germ-cell
production is impaired. Examples include testicular
dysgenesis and Kallmann syndrome (isolated hypo-
gonadotropic hypogonadism with hyposmia).
Dissociated hypogonadism
Dissociated hypogonadism is characterized by primary
damage in a specific testicular cell population. In the short
or long term, the production of other populations becomes
impaired at different degrees. Some examples include
Leydig cell hypoplasia secondary to LHCG-R mutations,
FSH deficiency for FSH beta-subunit gene mutations
involving Sertoli cells, and post-chemotherapy gonadal
failure, which primarily damages germ cells.
Hypogonadism of fetal, childhood, pubertal
or adult onset
The clinicalmanifestations of hypogonadismare dependent
on the period of life where failure occurs. Fetal hypo-
gonadism established during the first trimester causes a
disorder of sex development (DSD), which manifests in the
form of ambiguous or female genitalia at birth [48]. Gonadal
dysgenesis is an example of generalized fetal hypogonad-
ism, whereas Leydig cell hypoplasia is a dissociated form.
Central hypogonadism does not result in genital ambiguity,
as Leydig cell function during the first trimester of gestation
is not dependent on pituitary gonadotropins, but on
placental hCG. Hypogonadism occurred from the second
trimester of fetal life, be it testicular, central or dual, results
in micropenis or cryptorchidism in males without genital
ambiguity [49–51]. As the HPG axis remains active for the
first 3–6 months of postnatal life [9, 10], this period repre-
sents a window of opportunity to establish a diagnosis of
hypogonadism [49–51].
Hypogonadism diagnosed in childhood may remain
unnoticed. This is due to the fact that HPG activity decreases
during childhood. For the condition to be diagnosed, sus-
picion or active screening is required (i. e., by baseline AMH
or inhibin B determination, ormeasuring testosterone levels
in response to hCG-induced stimulation). Otherwise, diag-
nosis will be delayed until puberty [52].
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At puberty, male hypogonadism is characterized by the
absence or interruption of normal pubertal development [22,
25]. As a result of androgen deficiency, secondary sex char-
acteristics do not appear, i. e., body proportions typically are
eunuchoid (upper/lower body proportion <1, with a span
exceeding 6 cm), deepening of the voice is compromised,
bone maturation is delayed, and testicular volume does not
increase, which indicates disturbed spermatogenesis.
Hypogonadismestablished in adulthood is characterized
by decreased libido, impotence and oligozoospermia [45].
Men of an older age may develop amild androgen deficiency
known as late-onset hypogonadism [53], which has similar
symptoms to those of hypogonadism in young men.
Clinical utility of HPG axis
biomarkers in childhood and
adolescence
From birth to 3–6 months of life
During this period, the HPG is active, and all hormones are
informative.
Newborns with ambiguous or female genitalia
In newbornswith ambiguous genitalia, the causes of a DSD
must be investigated. In patients with a 46,XY karyotype,
the cause may be gonadal dysgenesis or generalized fetal‐
onset primary hypogonadism established in the first
trimester of gestation. These patients generally exhibit very
low levels of AMH, inhibin B, testosterone and INSL3,
whereas gonadotropins are elevated [48, 51, 54]. Imaging
studies demonstrate the presence of uterus and fallopian
tubes due to AMH deficiency. When genital ambiguity co-
occurs with the absence of Müllerian structures, the cause
may be dissociated primary fetal hypogonadism with a
specific failure of the Leydigian sector. The causes may be
Leydig cell hypoplasia secondary to LHCG-R mutations or
an abnormality in the proteins involved in testicular ste-
roidogenesis [55]. Differential diagnosis from gonadal
dysgenesis is based on the presence of low testosterone
levels, high LH levels, and AMH levels within normal range
for males [56]. Hypogonadism is excluded when testos-
terone and AMH concentrations are high. Then, the cause
of DSD may be insensitivity to androgens secondary to
androgen-receptor mutations, a deficient DHT production
in peripheral tissues secondary to 5α-reductase mutations,
or a non-endocrine cause [48, 54, 57]. In patients with sex
chromosome anomalies (i. e., deletions of the short arm of
the Y chromosome; 45,X/46,XY or other mosaicisms
involving the presence of the Y-chromosome), the cause of
the DSD is gonadal dysgenesis.
A rare form of DSD 46,XY is persistent Müllerian duct
syndrome (PMDS), which is characterized by cryptorchi-
dism and fully-developed male genitals. Gonadotropins
and testosterone are within the normal range for males,
whereas AMH is very low or undetectablewhen the cause is
an AMH mutation, and normal in AMHR2 mutations [58].
The first case corresponds to dissociated primary fetal
hypogonadism specifically affecting Sertoli cells. The sec-
ond case corresponds to peripheral resistance toAMH,with
the absence of hypogonadism.
In newborns with karyotype 46,XX, genital ambiguity
occurs as the result of excess suprarenal (i. e., congenital
suprarenal hyperplasia) [59] or placental androgen produc-
tion (aromatase deficiency) [60]. These patients haveovaries,
andAMHand inhibinB concentrations arewithin thenormal
range for females [56]. Nevertheless, genital ambiguity may
be secondary to testicular tissue development in the form of
ovotestis or dysgenetic testis [61]. In the two first cases, AMH
and testosterone are generally in an intermediate point be-
tween normal ranges for males and females, whereas go-
nadotropins can be elevated or even within normal range in
the presence of functional ovarian tissue. Cases have been
reported of males born with karyotype 46,XX and normal
male genitalia. The detection of these cases is based on
discordance with an eventual karyotype developed during
gestation. These patients exhibit normal HPG axis hormone
levels for males until puberty, as described below.
Newborns with micropenis, cryptorchidism, and/or
micro-orchidism
Micropenis, cryptorchidismand/ormicro-orchidismare signs
of HPG axis failure. This type of fetal hypogonadism estab-
lishes from the second trimester of gestation after male gen-
ital differentiation has started. Co-occurrence of low levels of
LH, FSH, testosterone, INSL3, AMH, and inhibin B is highly
suggestive of central fetal hypogonadism (hypogonado-
tropin) affecting allHPGaxis sectors [34, 51, 62–64].However,
these low levels may also be due to a generalized primary
testicular failure from the second trimester of gestation. TRS is
characterized by undetactable levels of testicular hormones
with elevated gonadotropin concentrations [51, 65].
From 6 months to pubertal age
In this period of life, gonadotropins, testosterone, and
INSL3 are uninformative, whereas Sertoli cells are of
greater clinical utility.
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If the condition is congenital but diagnosis was
delayed, identifying the cause of the problem may be
challenging. Low levels of AMH and inhibin B are indica-
tive of Sertoli cell deficiency. However, it is difficult to
establish whether the disorder is secondary to a primary
testicular failure or a HPG axis failure. Gonadotropins may
normalize during childhood in patients with primary
hypogonadism (dysgenetic DSD or DSD caused by Leydig
cell dysfunction, TRS or anorchidism). Otherwise said,
primary male hypogonadism is not always "hyper-
gonadotropic" at prepubertal age [28]. These patients show
normal testosterone levels (i. e., undetectable), unless an
hCG stimulation test is performed to determine the pres-
ence of functional Leydig cells. Undetectable levels of AMH
and inhibin B are confirmatory of anorchidism.
In children without a perinatal history of micropenis,
the probability of fetal hypogonadism is lower. Finding is
generally incidental and occurs during evaluation of
cryptorchidism, torsion, testicular trauma or oncologic
treatments that may affect gonadal function. Again, go-
nadotropins and basal testosterone have poor diagnostic
value, as gonadotropins do not increase during childhood,
which is the period in which gonadal damage occurs (from
6 months of life) [28]. In patients without palpable gonads,
detectable levels of AMH [66] or inhibin B [67] guarantees
the presence of ectopic gonads, and testosterone levels
increase after a hCG stimulation test [66]. Low levels of
AMH [52, 66, 68, 69] or inhibin B [67, 68] are indicative of an
abnormal testicular function. Cases have been reported of
childrenwithmonorchidismwith normal AMH and inhibin
B values [70]. Circulating levels of INSL3 are not of clinical
utility in this age group [71].
At pubertal age
The absence of signs of pubertal development is suggestive
of androgen deficiency. Although this abnormality can be
secondary to primary hypogonadism, a testicular failure
rarely affects the Leydig population, thereby inhibiting
androgen secretion completely. In primary hypogonadism,
the structures most frequently affected is the tubular
sector, which translates into a small testicular volume [72].
Examples of this condition include Klinefelter syndrome
[73, 74], XX males [75] and patients receiving chemo-
therapy [69]. These patients generally exhibit normal
circulating levels of testicular hormones and gonadotro-
pins until Tanner stage 3 of pubertal development. Then,
primary hypogonadism becomes "hypergonadotropic".
Most frequently, the absence of pubertal development
can be due to an HPG axis failure in the form of congenital
or acquired central hypogonadism, a delayed reactivation
of the HPG axis, or simple delayed puberty [22]. Differential
diagnosis is challenging. Once general causes such as
acute or chronic systemic diseases have been excluded,
circulating levels of HPG-axis hormones are not necessarily
informative. Gonadotropin concentrations at prepubertal
levels are not of utility in differential diagnosis of central
hypogonadism and simple delayed puberty, andGnRH [76]
(or analogs) stimulation tests are required [77]. The pres-
ence of other pituitary deficiencies facilitates diagnosis, as
they are indicative of gonadotropin deficiency. Testos-
terone and INSL3 remain at prepubertal levels and are not
useful to distinguish central hypogonadism from simple
delayed puberty [78]. In contrast, diagnosis is confirmed by
AMHand inhibin B levels, as they are lower in patientswith
central hypogonadism as compared to those with simple
delayed puberty [78, 79].
As in primary hypogonadism, central hypogonadism
can affect all cell populations (i. e., generalized) or initially
affect a single sector of the HPG axis. Examples of disso-
ciated central hypogonadism include tachykinin Precursor
3 (TAC3) and tachykinin receptor 3 (TACR3) mutations [80]
and LH beta sub-unit mutations [81], which manifest in the
form of low LH levels and normal FSH levels. Other ex-
amples are FSH beta subunit mutations [82], which are
associated with a decline in FSH and LH production and
normal androgen levels.
Dual hypogonadism is characterized by concomitant
HPG axis and gonad dysfunction. This condition can be
congenital of which hypogonadism is a late manifestation,
as in the case of Prader–Willi syndrome [83, 84] and
delayed-onset X-linked adrenal hypoplasia congenita due
to dosage-sensitive sex reversal, adrenal hypoplasia crit-
ical region, on chromosome X, gene 1 (DAX-1) gene muta-
tions [85]. Dual hypogonadism can also be acquired as in
the case of patients exposed to chemotherapy, which pri-
marily affects the testes, and cranial radiotherapy, which
affects the hypothalamus. Although gonadal hormone
levels are low, gonadotropins do not increase. In other
words, these conditions mimic eugonadotropic hypo-
gonadism.
Conclusions
Hypogonadism may have a fetal or postnatal origin and
has different clinical manifestations according to the
period of life in which it is established. This condition may
affect any functional testicular component, or initially
involve a single component, thereby resulting in specific
clinical and biochemical manifestations. Primary damage
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generally occurs to the gonads or the HPG axis and rarely
affects the two systems concomitantly. Gonadotropins and
androgens are useful biomarkers in newborns andpubertal
males, whereas AMH and inhibin B aremore informative in
childhood.
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